Christine Ring - Jan 10, 2022 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
General Counsel
Signature
/s/ Christine Ring
Stock symbol
NRIX
Transactions as of
Jan 10, 2022
Transactions value $
-$30,336
Form type
4
Date filed
1/11/2022, 03:10 PM
Previous filing
Dec 13, 2021
Next filing
Jan 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $2.23K +1.2K +93.31% $1.86* 2.49K Jan 10, 2022 Direct F1
transaction NRIX Common Stock Sale -$32.6K -1.2K -48.27% $27.14 1.29K Jan 10, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -1.2K -1.18% $0.00 100K Jan 10, 2022 Common Stock 1.2K $1.86 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 The option vests as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares will vest monthly thereafter until the option is fully vested on August 9, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.